Your browser doesn't support javascript.
loading
In vivo CRISPR screens identify a dual function of MEN1 in regulating tumor-microenvironment interactions.
Su, Peiran; Liu, Yin; Chen, Tianyi; Xue, Yibo; Zeng, Yong; Zhu, Guanghui; Chen, Sujun; Teng, Mona; Ci, Xinpei; Guo, Mengdi; He, Michael Y; Hao, Jun; Chu, Vivian; Xu, Wenxi; Wang, Shiyan; Mehdipour, Parinaz; Xu, Xin; Marhon, Sajid A; Soares, Fraser; Pham, Nhu-An; Wu, Bell Xi; Her, Peter Hyunwuk; Feng, Shengrui; Alshamlan, Najd; Khalil, Maryam; Krishnan, Rehna; Yu, Fangyou; Chen, Chang; Burrows, Francis; Hakem, Razqallah; Lupien, Mathieu; Harding, Shane; Lok, Benjamin H; O'Brien, Catherine; Berlin, Alejandro; De Carvalho, Daniel D; Brooks, David G; Schramek, Daniel; Tsao, Ming-Sound; He, Housheng Hansen.
Afiliação
  • Su P; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
  • Liu Y; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Chen T; Department of Laboratory Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
  • Xue Y; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Zeng Y; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Zhu G; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Chen S; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Teng M; West China School of Public Health and West China Fourth Hospital, and State Key Laboratory of Biotherapy, Sichuan University, Chengdu, China.
  • Ci X; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Guo M; West China School of Public Health and West China Fourth Hospital, and State Key Laboratory of Biotherapy, Sichuan University, Chengdu, China.
  • He MY; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
  • Hao J; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Chu V; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Xu W; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Wang S; Department of Immunology, University of Toronto, Toronto, Ontario, Canada.
  • Mehdipour P; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Xu X; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Marhon SA; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
  • Soares F; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Pham NA; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Wu BX; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Her PH; Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
  • Feng S; Ludwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Alshamlan N; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Khalil M; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Krishnan R; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Yu F; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Chen C; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
  • Burrows F; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Hakem R; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
  • Lupien M; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Harding S; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
  • Lok BH; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • O'Brien C; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Berlin A; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • De Carvalho DD; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
  • Brooks DG; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Schramek D; Department of Laboratory Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
  • Tsao MS; Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
  • He HH; Kura Oncology Inc, San Diego, CA, USA.
Nat Genet ; 56(9): 1890-1902, 2024 Sep.
Article em En | MEDLINE | ID: mdl-39227744
ABSTRACT
Functional genomic screens in two-dimensional cell culture models are limited in identifying therapeutic targets that influence the tumor microenvironment. By comparing targeted CRISPR-Cas9 screens in a two-dimensional culture with xenografts derived from the same cell line, we identified MEN1 as the top hit that confers differential dropout effects in vitro and in vivo. MEN1 knockout in multiple solid cancer types does not impact cell proliferation in vitro but significantly promotes or inhibits tumor growth in immunodeficient or immunocompetent mice, respectively. Mechanistically, MEN1 knockout redistributes MLL1 chromatin occupancy, increasing H3K4me3 at repetitive genomic regions, activating double-stranded RNA expression and increasing neutrophil and CD8+ T cell infiltration in immunodeficient and immunocompetent mice, respectively. Pharmacological inhibition of the menin-MLL interaction reduces tumor growth in a CD8+ T cell-dependent manner. These findings reveal tumor microenvironment-dependent oncogenic and tumor-suppressive functions of MEN1 and provide a rationale for targeting MEN1 in solid cancers.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Histona-Lisina N-Metiltransferase / Proteínas Proto-Oncogênicas / Linfócitos T CD8-Positivos / Microambiente Tumoral / Sistemas CRISPR-Cas Limite: Animals / Female / Humans Idioma: En Revista: Nat Genet Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Histona-Lisina N-Metiltransferase / Proteínas Proto-Oncogênicas / Linfócitos T CD8-Positivos / Microambiente Tumoral / Sistemas CRISPR-Cas Limite: Animals / Female / Humans Idioma: En Revista: Nat Genet Ano de publicação: 2024 Tipo de documento: Article